Results 41 to 50 of about 206,338 (257)

Perillyl Alcohol Is an Angiogenesis Inhibitor

The Journal of Pharmacology and Experimental Therapeutics, 2004
Aberrant angiogenesis is essential for the progression of solid tumors and hematological malignancies. Thus, antiangiogenic therapy is one of the most promising approaches to control cancer. In the present work, we examined the ability of perillyl alcohol (POH), a dietary monoterpene with well-established tumor chemopreventive and chemotherapeutic ...
Loutrari, H., Hatziapostolou, M., Skouridou, V., Papadimitriou, E., Roussos, C., Kolisis, F.N., Papapetropoulos, A.   +6 more
openaire   +3 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

The Hemostatic System and Angiogenesis in Malignancy

Neoplasia: An International Journal for Oncology Research, 2001
Coagulopathy and angiogenesis are among the most consistent host responses associated with cancer. These two respective processes, hitherto viewed as distinct, may in fact be functionally inseparable as blood coagulation and fibrinolysis, in their own ...
Marek Z. Wojtukiewicz, Ewa Sierko, Petr Klementt, Janusz Rak   +3 more
doaj   +1 more source

Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

BMC Genomic Data, 2022
Highlights Recent studies have focused on the development of indirect angiogenesis inhibitors. Bioinformatics-based identification of potential rosiglitazone target genes to inhibit breast cancer angiogenesis.
Adam Hermawan, Herwandhani Putri
doaj   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Ezetimibe Is an Inhibitor of Tumor Angiogenesis [PDF]

The American Journal of Pathology, 2009
Epidemiological and preclinical observations have suggested a role for one or more products of the mevalonate/cholesterol biosynthesis pathway in the progression of prostate cancer. In this study, we used ezetimibe (Zetia), a specific, FDA-approved, cholesterol uptake-blocking drug, in combination with either a hyper- or hypocholesterolemic diet, to ...
Keith R, Solomon, Kristine, Pelton, Kelly, Boucher, Jinsoo, Joo, Christopher, Tully, David, Zurakowski, Carl P, Schaffner, Jayoung, Kim, Michael R, Freeman   +8 more
openaire   +2 more sources

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

Acta Pharmaceutica Sinica B, 2020
Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment.
Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong Liu   +14 more
doaj   +1 more source

Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Clinical Case Reports, 2021
Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric ...
Sewanti Limaye, Darshana Patil, Dadasaheb Akolkar, Navin Srivastava, Revati Patil, Sachin Apurwa, Sanket Patil, Jinumary John, Rahul Gosavi, Prabhu Nesargikar, Prashant Kumar, Vineet Datta, Chirantan Bose, Zarrine Raazi, Ajay Srinivasan, Rajan Datar   +15 more
doaj   +1 more source

Metalloproteinases and their inhibitors in tumor angiogenesis [PDF]

International Journal of Cancer, 2005
AbstractAngiogenesis is the process by which new blood vessels are formed from preexisting vasculature. It is an essential feature of the female reproductive cycle, embryonic development and wound repair. Angiogenesis has also been identified as a causal or contributing factor in several pathologies, including cancer, where it is a rate‐limiting step ...
Handsley, M.M., Edwards, D.R.
openaire   +3 more sources